Reference intervals and decision limits for B-type natriuretic peptide (BNP) and its precursor (Nt-proBNP) in the elderly

Clinica Chimica Acta

Volumn 382, Issue 1-2, 2007, Pages 8-14

  Alehagen, Urban ^a   Goetze, Jens Peter ^b   Dahlström, Ulf ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b Mental Health Services CPH   (Denmark)

Author keywords

Heart failure; Natriuretic peptides; Reference values

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; HORMONE PRECURSOR; PEPTIDE DERIVATIVE;

AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL PRACTICE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DECISION MAKING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; REFERENCE VALUE; REGISTRATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; REFERENCE VALUES;

EID: 34249096475     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.03.005     Document Type: Article

References (30)

1. Goetze J.P. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin Chem 50 (2004) 1503-1510
2. Groenning B.A., Raymond I., Hildebrandt P.R., Nilsson J.C., Baumann M., and Pedersen F. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 90 (2004) 297-303
3. Alehagen U., Lindstedt G., Levin L.A., and Dahlstrom U. Risk of cardiovascular death in elderly patients with possible heart failure B-type natriuretic peptide (BNP) and the aminoterminal fragment of ProBNP (N-terminal proBNP) as prognostic indicators in a 6-year follow-up of a primary care population. Int J Cardiol 100 (2005) 125-133
4. Bertinchant J.P., Combes N., Polge A., et al. Prognostic value of cardiac troponin T in patients with both acute and chronic stable congestive heart failure: comparison with atrial natriuretic peptide, brain natriuretic peptide and plasma norepinephrine. Clin Chim Acta 352 (2005) 143-153
5. Heeschen C., Hamm C.W., Mitrovic V., Lantelme N.H., and White H.D. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 110 (2004) 3206-3212
6. Latini R., Masson S., Anand I., et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 25 (2004) 292-299
7. Richards M., and Troughton R.W. NT-proBNP in heart failure: therapy decisions and monitoring. Eur J Heart Fail 6 (2004) 351-354
8. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., and Burnett Jr. J.C. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40 (2002) 976-982
9. Bay M., Kirk V., Parner J., et al. NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart 89 (2003) 150-154
10. Clerico A., Del Ry S., Maffei S., Prontera C., Emdin M., and Giannessi D. The circulating levels of cardiac natriuretic hormones in healthy adults; effects of age and sex. Clin Chem Lab Med 40 (2002) 371-377
11. Alehagen U., Eriksson H., Nylander E., and Dahlström U. Heart failure in the elderly. Characteristics of a Swedish primary health care population. Heart Drug 2 (2002) 211-220
12. Alehagen U., Lindstedt G., Levin L.A., and Dahlstrom U. The risk of cardiovascular death in elderly patients with possible heart failure. Results from a 6-year follow-up of a Swedish primary care population. Int J Cardiol 100 (2005) 17-27
13. Karl J., Borgya A., Gallusser A., et al. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl 230 (1999) 177-181
14. Solberg H.E. RefVal: a program implementing the recommendations of the International Federation of Clinical Chemistry on the statistical treatment of reference values. Comput Methods Programs Biomed 48 (1995) 247-256
15. Solberg H.E. The IFCC recommendation on estimation of reference intervals. The RefVal program. Clin Chem Lab Med 42 (2004) 710-714
16. Efron B., and Tibshirani R. An introduction to the Bootstrap (1993), Chapman and Hall/ CRC, New York
17. Solberg H.E., and Lahti A. Detection of outliers in reference distributions: performance of Horn's algorithm. Clin Chem 51 (2005) 2326-2332
18. Ueda R., Yokouchi M., Suzuki T., Otomo E., and Katagiri T. Prognostic value of high plasma brain natriuretic peptide concentrations in very elderly persons. Am J Med 114 (2003) 266-270
19. Suzuki T., Yamaoki K., Nakajima O., et al. Screening for cardiac dysfunction in asymptomatic patients by measuring B-type natriuretic peptide levels. Jpn Heart J 41 (2000) 205-214
20. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 (2003) 1011-1053
21. Wang T.J., Larson M.G., Levy D., et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 90 (2002) 254-258
22. Yu C.M., Sanderson J.E., Shum I.O., et al. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern. Eur Heart J 17 (1996) 1694-1702
23. Ry S.D., Clerico A., Giannessi D., et al. Measurement of brain natriuretic peptide in plasma samples and cardiac tissue extracts by means of an immunoradiometric assay method. Scand J Clin Lab Invest 60 (2000) 81-90
24. Vasan R.S., Benjamin E.J., Larson M.G., et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 288 (2002) 1252-1259
25. Hogenhuis J., Voors A.A., Jaarsma T., Hillege H.L., Boomsma F., and van Veldhuisen D.J. Influence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/NT-ANP and BNP/NT-proBNP. Eur J Heart Fail 7 (2005) 81-86
26. Maisel A., Hollander J.E., Guss D., et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 44 (2004) 1328-1333
27. Goetze J.P., Gore A., Moller C.H., Steinbruchel D.A., Rehfeld J.F., and Nielsen L.B. Acute myocardial hypoxia increases BNP gene expression. FASEB J 18 (2004) 1928-1930
28. Schnabel R., Lubos E., Rupprecht H.J., et al. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study. J Am Coll Cardiol 47 (2006) 552-558
29. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Rev Esp Cardiol 58 (2005) 1062-1092
30. Henry W.L., Gardin J.M., and Ware J.H. Echocardiographic measurements in normal subjects from infancy to old age. Circulation 62 (1980) 1054-1061